רווח למניה בשנים עשר החודשים האחרונים: Renovaro Biosciences (RENB)

High cash burn and a lack of profitability create significant financial risks, as evidenced by the TTM fundamental earnings per share trend, where -4.70 represents the current metric. Renovaro Inc. (RENB) relies on a multidisciplinary staff of AI specialists, navigating the uncertainty of clinical trials through a strategic pivot toward developing an early cancer diagnosis platform.
פילוחים אנליטיים ודוחות נתונים של חברת Renovaro Inc. (RENB)

Renovaro Inc. automates the search for anti-tumor therapies by utilizing AI and robotic platforms to analyze gene mutations. The EPS TTM figure reflects the net income allocated per common share over a trailing twelve-month period. This metric allows investors to assess the actual monetization efficiency of bioinformatics developments. It serves as a filter for determining the operational resilience of the business. Analyzing the trailing 12-month EPS chart on GURU.Markets helps capture trend reversals prior to official reports.